July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Improvement and stabilization of vision for 18 months after Human Embryonic Stem-cell (hESC) derived, RPE-sheet transplantation on a synthetic basement membrane for trestment of severe, wet Age-Related Macular Degeneration
Author Affiliations & Notes
  • Lyndon daCruz
    ORBIT, Institute of Ophthalmology, University College London (UCL), The London Project to Cure Blindness , London, United Kingdom
    VR surgery, NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology , London, United Kingdom
  • Kate Fynes
    ORBIT, Institute of Ophthalmology, University College London (UCL), The London Project to Cure Blindness , London, United Kingdom
  • Odysseas Georgiadis
    Vitreo - retinal Surgery, Moorfields Eye Hospital, London, United Kingdom
  • Britta Nommiste
    ORBIT, Institute of Ophthalmology, University College London (UCL), The London Project to Cure Blindness , London, United Kingdom
  • Amanda-Jayne Francis Carr
    Institute of Ophthalmology, University College London (UCL), London, United Kingdom
  • Conor Ramsden
    ORBIT, Institute of Ophthalmology, University College London (UCL), The London Project to Cure Blindness , London, United Kingdom
  • Anthony Vugler
    Institute of Ophthalmology, University College London (UCL), London, United Kingdom
  • Paul Whiting
    University College London, Institute of Neurology, Queens Square, London, United Kingdom
  • Peter Loudon
    Pfizer, Granta Park, Cambridge, United Kingdom
  • Peter J Coffey
    ORBIT, Institute of Ophthalmology, University College London (UCL), The London Project to Cure Blindness , London, United Kingdom
  • Footnotes
    Commercial Relationships   Lyndon daCruz, International Patent Application No. PCT/GB2009/000917 International Patent Application No. PCT/GB2011/051262 (P); Kate Fynes, None; Odysseas Georgiadis, None; Britta Nommiste, None; Amanda-Jayne Carr, None; Conor Ramsden, None; Anthony Vugler, None; Paul Whiting, Pfizer (E); Peter Loudon, Pfizer (E); Peter Coffey, International Patent Application No. PCT/GB2009/000917 International Patent Application No. PCT/GB2011/051262 (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2985. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lyndon daCruz, Kate Fynes, Odysseas Georgiadis, Britta Nommiste, Amanda-Jayne Francis Carr, Conor Ramsden, Anthony Vugler, Paul Whiting, Peter Loudon, Peter J Coffey; Improvement and stabilization of vision for 18 months after Human Embryonic Stem-cell (hESC) derived, RPE-sheet transplantation on a synthetic basement membrane for trestment of severe, wet Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2985.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report clinical outcomes from the first 2 patients in a prospectice phase 1 trial of hESC derived sheet-RPE transplantation as a possible treatment for severe, wet Age-related Macular Degeneration (Clinical Trials.gov: NCT01691261).

Methods : Surgical delivery of hESC-derived RPE, on a human vitronectin-coated artificial basement membrane, into the submacular space, was carried out within 6 weeks of sudden vision loss from severe wet age-related macular degeneration. Immunosuppression consisted of short-course perioperative oral prednislone and long-term local depot administration of fluoqinolone. Visual function assessments pre and post surgery were completed by masked optometrists and consisted of best corrected, Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (BCVA), Minnesota MN Read, Pelli-Robson contrast sensitivity and Nidek Microperimeter based fixation and retinal sensitivity over the transplanted RPE sheet.

Results : The ETDRS BCVA improved from 10 to 39 and from 8 to 27 letters over 18 months in cases 1 and 2 respectively. Fixation in case 1 was stable at year 1 (83% within 2° and 100% within 4°) but became unstable at month 18 (17% within 2° and 70% within 4°). In case 2 however, fixation was stable at both year 1 (98% within 2° and 100% within 4°) and month 18 (81% within 2° and 100% within 4°). Fixation remained at the geometric centre of the patch (pre-op fovea) in case 2 but moved from the centre to the edge of the patch in case 1. Micro-perimetry showed visual sensitivity over the patch in both cases. Reading speed improved from 1.7 to 82.8 and 0 to 47.8 words/min in case 1 and 2 respectively at 12 months. Pelli-Robson contrast sensitivity scores (Log) improved from 0.45 to 1.35 in case 1 and 0 to 1.05 in case 2 at 12 months.

Conclusions : The hESC-derived-RPE therapeutic element was delivered successfully and continued to function with evidence of sustained visual recovery for 18 months in 2 patients. Sustained survival and function of the RPE was achieved using intra-ocular steroid implants with no long-term, systemic immunosuppression. This work supports the feasibility and safety of hESC-derived RPE transplantation as a regenerative strategy for AMD and as a broader treatment paradigm for hESC-derived tissue transplantation.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×